The month of November brings lung cancer into focus. Over the past few years great strides have been made in the management of non small cell lung cancer due to the advancement of precision cancer medicines and immunotherapy.
Lung cancer remains the second most common cancer in women (behind breast cancer) and also the second most common in men (behind prostate cancer). In 2019, there will be approximately 225,000 individuals diagnosed with lung cancer in the United States.
Staying informed with the latest news on prevention, screening of high risk individuals, and treatment advances are all important in order to reducing the risk of developing lung cancer, ensure optimal care and achieve the best possible outcomes.
Featured This Month on Cancer Connect
CancerConnect partnered with Dana-Farber Cancer Institute to provide you with the opportunity to engage with a lung cancer expert, David M. Jackman, MD, who answered questions and relayed important information about lung cancer. Dr. Jackman is a thoracic oncologist in the Lowe Center for Thoracic Oncology at Dana-Farber. Dr. Jackman focuses on lung cancer and mesothelioma. His clinical research interests include evaluating how to predict responses to targeted therapy in non-small cell lung cancer (NSCLC).